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Abstract
The aim of this study was to investigate succinate dehydrogenase (SDH) expression in breast cancer according to
breast cancer molecular subtype using immunohistochemistry and to assess the clinical implications of SDH
expression. Immunohistochemical staining for ER, PR, HER-2, Ki-67, HIF-1α, SDHA, and SDHB was performed on
tissue microarrays of 721 breast cancers. According to the immunohistochemistry results for ER, PR, HER-2, and Ki-67
and fluorescence in situ hybridization (FISH) results for HER-2, breast cancer molecular subtypes were classified into
luminal A, luminal B, HER-2, and triple-negative breast cancer (TNBC). HER-2 subtype breast cancers most frequently
showed high-level expression of SDHA in tumor cells, while the luminal A subtype most frequently showed low or
negative expression of SDHA in tumor cells (P = 0.032). Stromal SDHB expression rate was highest in HER-2 subtype
and lowest in TNBC (P < 0.001). SDHA-negative breast cancers were associated with younger age at diagnosis
(P = 0.012), and SDHB-negative breast cancers with lower histologic grade (P = 0.044) and lower Ki-67 labeling
index (LI) (P = 0.046). Tumor phenotypes according to the SDH status were SDHA(+)/SDHB(+) > SDHA(–)/SDHB
(–) > SDHA(–)/SDHB(+) > SDHA(+)/SDHB(–) in order of frequency. The stromal phenotypes were SDHA(–)/SDHB
(–) > SDHA(+)/SDHB(+) > SDHA(–)/SDHB(+) > SDHA(+)/SDHB(–). In conclusion, loss of SDHA or SDHB expression
was observed in about 3% of breast cancers in this study. Low SDH expression status in breast tumor cells was
associated with younger age at diagnosis and low-grade histology.
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Introduction
Succinate dehydrogenase (SDH) (succinate-coenzyme Q
reductase, respiratory Complex II) catalyzes the oxidation
of succinate to fumarate with the reduction of ubiquinone
to ubiquinol. Through the coupling of these two reactions
in the inner mitochondrial membrane, SDH links glucose
oxidation in the TCA cycle with ATP production in the
mitochondria (Cardaci & Ciriolo 2012; King et al. 2006;
Barletta & Hornick 2012; Van Nederveen et al. 2009).
SDH is composed of four subunits; SDHA, SDHB, SDHC
and SDHD. The first two are hydrophilic proteins pro-
truding into the mitochondrial matrix, and the second
two are hydrophobic proteins that anchor the catalytic
core into the inner mitochondrial membrane (Cardaci &
Ciriolo 2012; King et al. 2006; Barletta & Hornick 2012;
Van Nederveen et al. 2009).
Germline loss-of-function SDH mutations are associ-
ated with several tumors such as pheochromocytoma and
paraganglioma, gastrointestinal stromal tumor (GIST),
and renal cell carcinoma (Hensen & Bayley 2011;
Kantorovich et al. 2010; Anderson et al. 2004; Astuti et al.
2001; Miettinen et al. 2011; Badve et al. 2011; Ricketts
et al. 2008). Among these, GIST and renal cell carcinoma
are reported to display histologic features that distinguish
SDH-deficient tumors (Miettinen et al. 2011). Although
SDH germline mutation may be accurately evaluated by
gene sequencing, a few recent studies have shown very
high sensitivity for immunohistochemical detection of
SDH mutation in GIST, pheochromocytoma, and
paraganglioma (Van Nederveen et al. 2009; Gill et al.
2010a; Miettinen et al. 2013; Janeway et al. 2011).
To date, few studies have investigated SDH expression
in breast cancer. We investigated SDH expression status
according to breast cancer molecular subtype using im-
munohistochemical methods and assessed the clinical
implications of SDH expression in breast cancer.
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Materials and methods
Patient selection
Patients who were diagnosed with invasive ductal carcin-
oma, not otherwise specified and underwent surgical exci-
sion at Severance Hospital between January 2002 and
December 2005 were included in the study. Patients who
received preoperative hormonal therapy or neoadjuvant
chemotherapy were excluded. All hematoxylin and eosin
(H&E)-stained slides for each case were retrospectively
reviewed by breast pathologists (Koo JS). The histological
grade was assessed using the Nottingham grading system.
(Elston & Ellis 1991) The clinicopathologic parameters
evaluated for each breast cancer included patient age at
initial diagnosis, lymph node metastasis, tumor recur-
rence, distant metastasis, and patient survival. The Institu-
tional Review Board of Yonsei University Severance
Hospital approved this study.
Tissue microarray
On H&E-stained slides of tumors, a representative area
was selected and a corresponding spot was marked on
the surface of the paraffin block. Using a biopsy needle,
the selected area was punched out and a 3-mm core of
tumor tissue was placed onto a 6 × 5 recipient block.
Two tissue cores were extracted from each sample to
minimize bias. Each tissue core was assigned a unique
microarray location number that was linked to clinico-
pathologic data in a database.
Immunohistochemistry
All immunohistochemical staining was performed on
formalin-fixed, paraffin-embedded tissue sections using
antibodies as indicated (Table 1). Briefly, 5-μm-thick sec-
tions were obtained with a microtome, transferred onto
adhesive slides, and dried at 62 °C for 30 min. After in-
cubation with primary antibodies, immunodetection was
performed with biotinylated antimouse immunoglobulin,
followed by peroxidase-labeled streptavidin using a la-
beled streptavidin biotin kit with 3,3′-diaminobenzidine
chromogen as substrate. The primary antibody incuba-
tion step was omitted in the negative control. Slides
were counterstained with Harris hematoxylin.
Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed by light
microscopy. Parameters such as ER, PR, and HER-2 sta-
tus were obtained from patients’ pathologic reports. A
cut-off value of 1% or more positively stained nuclei was
used to define ER and PR positivity (Hammond et al.
2010). HER-2 staining was analyzed according to the
American Society of Clinical Oncology (ASCO)/College
of American Pathologists (CAP) guidelines using the fol-
lowing categories: 0, no immunostaining; 1+, weak in-
complete membranous staining, less than 10% of tumor
cells; 2+, complete membranous staining, either uniform
or weak in at least 10% of tumor cells; and 3+, uniform
intense membranous staining in at least 30% of tumor
cells (Wolff AC, et al. 2007). HER-2 immunostaining
was recorded as positive when strong (3+) membranous
staining was observed, whereas staining categories 0 to 1+
were recorded as negative. Samples showing 2+ HER-2 ex-
pression were evaluated for HER-2 amplification by fluor-
escence in situ hybridization (FISH).
Immunohistochemical staining for SDHA and SDHB
showed cytoplasmic expression with a granular pattern.
Complete loss of expression was considered negative,
while cytoplasmic expression in less than 50% of tumor
cells was considered low expression, and cytoplasmic ex-
pression in more than 50% of tumor cells was consid-
ered high expression (Figure 1). HIF-1α was considered
positive when more than 10% of tumor cells showed
strong cytoplasmic or nuclear expression.
Fish analysis
FISH was performed using a PathVysion HER-2 DNA
Probe Kit (Vysis, Downers Grove, IL, USA) according to
the manufacturer’s instructions. Invasive tumors were first
examined on hematoxylin-eosin-stained slides to confirm
histology. HER-2 gene copy number on the slides was
evaluated using an epifluorescence microscope (Olympus,
Tokyo, Japan) according to the ASCO/CAP guidelines
(Wolff AC, et al. 2007). At least 60 tumor cell nuclei in
three separate regions were investigated for HER-2 and
chromosome 17 signals. An absolute HER-2 gene copy
number lower than 4 or an HER-2 gene/chromosome 17
copy number ratio (HER-2/Chr17 ratio) less than 1.8 was
considered HER-2-negative. An absolute HER-2 copy
number between 4 and 6 or an HER-2/Chr17 ratio be-
tween 1.8 and 2.2 was considered HER-2-equivocal.
An absolute HER-2 copy number greater than 6 or an
HER-2/Chr17 ratio higher than 2.2 was considered HER-2-
positive.
Table 1 Clone, dilution, and source of antibodies used
Antibody Clone Dilution Company
HIF-1α EP1215Y 1:100 Biocare, Yorba Linda, CA, USA
SDHA 2E3GC12FB2AE2 1:100 Abcam, Cambridge, UK
SDHB 21A11AE7 1:100 Abcam, Cambridge, UK
Tumor phenotype-related
ER SP1 1:100 Thermo Scientific, CA, USA
PR PgR 1:50 DAKO, Denmark
HER-2 Polyclonal 1:1500 DAKO, Denmark
Ki-67 MIB-1 1:150 DAKO, Glostrup, Denmark
ER estrogen receptor; PR progesterone receptor, EGFR epidermal growth
factor receptor.
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Tumor phenotype classification
Breast cancer phenotypes were classified according to
the immunohistochemistry results for ER, PR, HER-2,
and Ki-67 and the FISH results for HER-2 as follows
(Goldhirsch A, et al. 2011): Luminal A subtype as ER-
or/and PR-positive and HER-2-negative and Ki-67
LI <14%; Luminal B subtype as ER- or/and PR-positive
and HER-2-negative and Ki-67 LI ≥14%; HER-2 positive
as ER- or/and PR-positive and HER-2 overexpressed or/
and amplified; HER-2-overexpression subtype as ER-
and PR-negative and HER-2 overexpressed or/and amp-
lified; and triple-negative breast cancer (TNBC) subtype
as ER-, PR-, and HER-2-negative.
Statistical analysis
Data were analyzed using SPSS for Windows, Version
12.0 (SPSS Inc., Chicago, IL, USA). Student’s t and Fisher’s
exact tests were used to evaluate continuous and categor-
ical variables, respectively. The significance level was set at
0.05. The time to tumor recurrence and overall survival
were evaluated by Kaplan-Meier and log-rank statistics.
Multivariate regression analysis was performed using the
Cox proportional hazards model.
Results
Patients’ characteristics
Clinicopathological characteristics according to breast
cancer molecular subtype are shown in Table 2. Molecular
subtypes among these 721 breast cancers included 302 lu-
minal A (41.9%), 168 luminal B (23.3%), 69 HER-2 type
(9.6%), and 182 TNBC (25.2%). TNBC showed higher
histologic grade (P < 0.001), higher T stage (P = 0.007), and
higher Ki-67 LI (P < 0.001) than other molecular sub-
types. The HER-2 subtype was positively associated
with age (P = 0.005) and with tumor recurrence and
death (P = 0.001).
HIF-1α and sdh status according to molecular subtype of
breast cancer
HIF-1α, SDHA, and SDHB expression according to
breast cancer subtype are shown in Table 3 and Figure 2.
Only 24 (3.3%) and 4 (0.6%) of 721 breast cancers
displayed HIF-1α expression in the nucleus and
cytoplasm, respectively. The HER-2 tumor subtype
showed the highest frequency of high SDHA expression,
and the luminal A subtype most frequently showed low
or negative SDHA expression (P = 0.032). Stromal SDHB
expression frequency was highest in the HER2 subtype
and lowest in TNBC (P < 0.001). Stromal SDHA expres-
sion was detected most frequently in the HER-2 subtype,
although the correlation was not significant (P = 0.063).
Nuclear HIF-1α expression and SDHA/SDHB expression
did not correlate significantly (Table 4); however, SDHA and
SDHB expression were correlated significantly (r = 0.895,
P < 0.001, Figure 3).
Clinicopathologic characteristics of breast cancer with
SDHA and/or SDHB negativity
Clinicopathologic characteristics of breast cancers were
compared between the SDHA/SDHB positive and nega-
tive breast cancers (Table 5). Tumor negativity for SDHA
correlated with earlier age at diagnosis of breast cancer
(P = 0.012) and with lower histologic grade (P = 0.062).
SDHB-negative breast cancer correlated with lower histo-
logic grade (P = 0.044) and lower Ki-67 LI (P = 0.046).
There was no correlation between the expression status of
SDH and that of nuclear HIF-1α (Table 4).
Correlations between clinicopathologic parameters and
expression of Hif-1α and SDH
Correlation analysis between HIF-1α and SDH expression
and clinicopathologic factors revealed an association of nu-
clear HIF-1α expression with PR negativity (P = 0.011), and
of low or negative SDHA expression in the tumor with ER
positivity (P = 0.044), HER-2 negativity (P = 0.021), and
higher T stage (P = 0.031). Low or negative SDHB expres-
sion in the tumor was associated with higher T stage
(P = 0.011). Stromal SDHB negativity was associated
with HER-2 negativity (P < 0.001, Table 6).
Clnicopathologic features according the phenotype of
SDH expression in breast cancer
The SDHA/SDHB expression phenotypes in these 712
breast tumors were, in order of frequency, SDHA
(+)/SDHB(+) > SDHA(-)/SDHB(–) > SDHA(-)/SDHB(+) >
SDHA(+)/SDHB(–). The stroma phenotypes were SDHA
Figure 1 Immunohistochemical evaluation of SDHB expression. (A) negative (B) low positive (C) high positive.
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(–)/SDHB(-) > SDHA(+)/SDHB(+) > SDHA(–)/SDHB(+) >
SDHA(+)/SDHB(–) (Table 7).
SDHA(+)/SDHB(+) tumors tended to have higher histo-
logic grades than SDHA(+)/SDHB(–) and SDHA(–)/SDHB
(-) tumors (P = 0.038). Stromal SDHA(–)/SDHB(+) tumors
showed the highest frequency of HER-2 positivity, while
stromal SDHA(+)/SDHB(-) tumors showed lowest HER-2
positivity (P = 0.001). Stromal SDHA/SDHB phenotype dif-
fered significantly between the molecular subtypes, SDHA
(+)/SDHB(+) being most frequent in Luminal A and least
in TNBC tumors. The SDHA(+)/SDHB(–) phenotype was
most frequent in TNBC and least frequent in HER-2 sub-
type tumors; SDHA(–)/SDHB(+) was most frequent in Lu-
minal B and least in TNBC; and SDHA(−)/SDHB(–) was
most frequent in the Luminal A and least in the HER-2
subtype (P < 0.001).
Prognostic significance of HIF-1α and SDH expression
status
In univariate analysis, neither HIF-1α nor SDH expression
was significantly related to patient outcome (Table 8). In
multivariate Cox analysis (Table 9), factors negatively as-
sociated with DFS were T stage (Hazard ratio: 2.535, 95%
CI: 1.376 − 4.670, P = 0.003), lymph node metastasis
(Hazard ratio: 2.257, 95% CI: 1.335 − 3.816, P = 0.002),
and high histologic grade (Hazard ratio: 1.685, 95% CI:
1.013 − 2.804, P = 0.045). Factors negatively associated
with OS were T stage (Hazard ratio: 2.218, 95% CI:
1.229 − 4.001, P = 0.008), lymph node metastasis (Hazard
ratio: 1.831, 95% CI: 1.076 − 3.115, P = 0.026), high tumor
expression of SDHA (Hazard ratio: 4.157, 95% CI: 1.657 −
10.432, P = 0.002), and low SDHB expression (Hazard ra-
tio: 3.223, 95% CI: 1.295 − 8.025, P = 0.012).
Table 2 Clinicopathologic characteristics according to breast cancer phenotype
Parameters Total n = 721 (%) Luminal A
n = 302 (%)
Luminal B
n = 168 (%)
HER-2
n = 69 (%)
TNBC
n = 182 (%)
P-value
Age (years, mean ± SD) 49.6 ± 10.9 50.6 ± 10.4 48.4 ± 10.0 52.4 ± 10.0 48.0 ± 12.4 0.005
Histologic grade <0.001
I 120 (16.6) 92 (30.5) 20 (11.9) 1 (1.4) 7 (3.8)
II 364 (50.5) 182 (60.3) 91 (54.2) 36 (52.2) 55 (30.2)
III 237 (32.9) 28 (9.3) 57 (33.9) 32 (46.4) 120 (65.9)
Tumor stage 0.007
T1 350 (48.5) 167 (55.3) 85 (50.6) 30 (43.5) 68 (37.4)
T2 356 (49.4) 127 (42.1) 81 (48.2) 38 (55.1) 110 (60.4)
T3 15 (2.1) 8 (2.6) 2 (1.2) 1 (1.4) 4 (2.2)
Nodal stage 0.060
N0 425 (58.9) 171 (56.6) 92 (54.8) 42 (60.9) 120 (65.9)
N1 192 (26.6) 89 (29.5) 43 (25.6) 13 (18.8) 47 (25.8)
N2 65 (9.0) 27 (8.9) 18 (10.7) 9 (13.0) 11 (6.0)
N3 39 (5.4) 15 (5.0) 15 (8.9) 5 (7.2) 4 (2.2)
Estrogen receptor status <0.001
Negative 261 (36.2) 5 (1.7) 5 (3.0) 69 (100.0) 182 (0.0)
Positive 460 (63.8) 297 (98.3) 163 (97.0) 0 (0.0) 0 (0.0)
Progesterone receptor status <0.001
Negative 346 (48.0) 49 (16.2) 46 (27.4) 69 (100.0) 182 (100.0)
Positive 375 (52.0) 253 (83.8) 122 (72.6) 0 (0.0) 0 (0.0)
HER-2 status <0.001
Negative 573 (79.5) 302 (100.0) 89 (53.0) 0 (0.0) 182 (100.0)
Positive 148 (20.5) 0 (0.0) 79 (47.0) 69 (100.0) 0 (0.0)
Ki-67 LI (%, mean ± SD) 17.3 ± 18.4 4.7 ± 3.7 19.6 ± 12.6 19.3 ± 12.8 35.1 ± 23.0 <0.001
Tumor recurrence 63 (8.7) 14 (4.6) 13 (7.7) 11 (15.9) 25 (13.7) 0.001
Patient death 60 (8.3) 12 (4.0) 13 (7.7) 11 (15.9) 24 (13.2) <0.001
Duration of clinical follow-up
(months, mean ± SD)
70.0 ± 31.2 72.4 ± 29.3 70.2 ± 30.0 65.2 ± 34.3 67.8 ± 34.2 0.234
TNBC triple negative breast cancer.
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Discussion
Germline defects in SDH, particularly in SDHA and SDHB,
have been detected in several tumor types, including pheo-
chromocytomas (Van Nederveen et al. 2009; Astuti et al.
2001), paragangliomas (Van Nederveen et al. 2009; Astuti
et al. 2001; Baysal 2003; Burnichon et al. 2010), GISTs (Gaal
et al. 2011; Gill et al. 2010b; Gill et al. 2011a), and renal cell
carcinomas (Gill et al. 2011b). Until recently, the ac-
curate detection of SDH mutation depended primarily
on direct sequencing and western blotting, methods
that a clinical laboratory may find too costly and time-
consuming. However, in a study of paraganglioma and
pheochromocytoma, Van Nederveen et al. demon-
strated the high sensitivity of immunohistochemical
Table 3 Expression of HIF-1α and SDH according to tumor phenotype
Parameters Total n = 721 (%) Luminal A n = 302 (%) Luminal B n = 168 (%) HER-2 n = 69 (%) TNBC n = 182 (%) P-value
Nuclear HIF-1α 0.319
Negative 697 (96.7) 296 (98.0) 161 (95.8) 65 (94.2) 175 (96.2)
Positive 24 (3.3) 6 (2.0) 7 (4.2) 4 (5.8) 7 (3.8)
Cytoplasmic HIF-1α 0.596
Negative 717 (99.4) 301 (99.7) 166 (98.8) 69 (100.0) 181 (99.5)
Positive 4 (0.6) 1 (0.3) 2 (1.2) 0 (0.0) 1 (0.5)
Tumoral SDHA 0.032
Negative/Low 41/319 (49.9) 21/143 (54.3) 8/76 (50.0) 5/19 (34.8) 7/81 (48.4)
High 361 (50.1) 138 (45.7) 84 (50.0) 45 (65.2) 94 (51.6)
Stromal SDHA 0.063
Negative 665 (92.2) 286 (94.7) 153 (91.1) 59 (85.5) 167 (91.8)
Positive 56 (7.8) 16 (5.3) 15 (8.9) 10 (14.5) 15 (8.2)
Tumoral SDHB 0.291
Negative/Low 24/245 (37.3) 15/103 (39.1) 3/56 (35.1) 3/19 (31.9) 3/67 (38.5)
High 452 (62.7) 184 (60.9) 109 (64.9) 47 (68.1) 112 (61.5)
Stromal SDHB <0.001
Negative 641 (88.9) 277 (91.7) 142 (84.5) 51 (73.9) 171 (94.0)
Positive 80 (11.1) 25 (8.3) 26 (15.5) 18 (26.1) 11 (6.0)
TNBC triple negative breast cancer.
Figure 2 Expression of SDHA and SDHB according to the molecular subtype of breast cancer. Tumor cells showed highest SDHA
expression in the HER-2 subtype and lowest SDHA expression in the luminal A subtype. Stromal elements expressed SDHA at lower levels than
tumor cells.
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methods to detect germline mutations in SDH (Van
Nederveen et al. 2009). While the tumors with SDHB,
SDHC, or SDHD germline mutations exhibited a loss
of SDHB immmunoexpression with intact SDHA ex-
pression, tumors with SDHA germline mutations
exhibited a loss of expression of both SDHA and
SDHB.
Using similar methods in the present study, we found
that 23 of 721 breast cancer patients (3.19%) had SDHA
mutation (SDHA–/SDHB– expression) and one patient
(0.1%) had an SDHB mutation (SHDA+/SDHB– expres-
sion; Table 7). As few previous studies have evaluated
SDH mutation in breast cancer, these findings provide a
starting point for future investigations. However, a
Table 4 Expression of SDHA and SDHB according to HIF-1α expression status
Factors Nuclear HIF-1α Cytoplasmic HIF-1α
Negative n = 697 (%) Positive n = 24 (%) P-value Negative n = 717 (%) Positive n = 4 (%) P-value
Tumoral SDHA 0.247 0.518
Negative 40 (5.7) 1 (4.2) 40 (5.6) 1 (25.0)
Low 311 (44.6) 8 (33.3) 318 (44.4) 1 (25.0)
High 346 (49.6) 15 (62.5) 359 (50.1) 50.0)
Stromal SDHA 0.423 1.000
Negative 644 (92.4) 21 (87.5) 661 (92.2) 4 (100.0)
Positive 53 (7.6) 3 (12.5) 56 (7.8) 0 (0.0)
Tumoral SDHB 0.926 0.032
Negative 24 (3.4) 0 (0.0) 23 (3.2) 1 (25.0)
Low 235 (33.7) 10 (41.7) 243 (33.9) 2 (50.0)
High 438 (62.8) 14 (58.3) 451 (62.9) 1 (25.0)
Stromal SDHB 0.328 1.000
Negative 621 (89.1) 20 (83.3) 637 (88.8) 4 (100.0)
Positive 76 (10.9) 4 (16.7) 80 (11.2) 0 (0.0)
SDH succinate dehydrogenase.
Figure 3 Correlation between SDHA and SDHB expression.
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previous study reported that SDH germline mutations or
variants occur in some patients with Cowden syndrome
(CS) who do not present the expected PTEN mutation.
Compared with patients positive for germline PTEN
mutation, these CS/CS-like individuals develop cancers
of the breast, thyroid, and kidney at higher frequencies
(Ni et al. 2008). Therefore, some breast cancer patients
may be expected to have SDH mutations.
Findings in this study may be limited in that the sensitiv-
ity of immunohistochemistry in detecting SDH mutation
as compared to direct sequencing has not been tested in
breast cancer. We have assumed a degree of reliability in
breast cancer similar to that of the detection of SDH
germline mutations in paraganglioma and pheochromocy-
toma (Van Nederveen et al. 2009). To confirm SDH muta-
tion, loss of SDH expression should be tested throughout
the entire tumor (Barletta & Hornick 2012), whereas in this
study, immunohistochemistry was performed on the tissue
microarray only.
In previous studies of pheochromocytoma and GIST,
SDH-deficient tumors showed complete loss of cytoplas-
mic granular expression (Miettinen et al. 2011; Gimenez-
Roqueplo et al. 2003). Even though weak, focal or diffuse
cytoplasmic staining was observed in a very few tumor
cells of SDH-deficient tumor, this finding may be consid-
ered negative, because it is clearly distinguishable from
the strong speckled expression pattern in surrounding
non-neoplastic elements. However, stromal cells did
not express SDHA and SDHB in most breast cancers
in this study, which made it impossible to compare the
staining intensity between tumor cells and internal
normal controls (stromal cells). Therefore, expression
in tumor cells was interpreted at three grade levels
according to the proportion of cells stained: grade (1),
Table 5 Clinicopathologic characteristics of breast cancer with SDHA and/or SDHB negativity in tumor cells
Parameters SDHA SDHB
Negative n = 41 (%) Positive n = 680 (%) P-value Negative n = 24 (%) Positive n = 697 (%) P-value
Age (years, mean ± SD) 45.4 ± 10.3 49.9 ± 10.9 0.012 46.9 ± 9.1 49.7 ± 10.9 0.212
Histologic grade 0.062 0.044
I/II 33 (80.5) 451 (66.3) 21 (87.5) 463 (66.4)
III 8 (19.5) 229 (33.7) 3 (12.5) 234 (33.6)
ER 0.405 0.286
Negative 12 (29.3) 249 (36.6) 6 (25.0) 255 (36.6)
Positive 29 (70.7) 431 (63.4) 18 (75.0) 442 (63.4)
PR 0.748 1.000
Negative 21 (51.2) 325 (47.8) 11 (45.8) 335 (48.1)
Positive 20 (48.8) 355 (52.2) 13 (54.2) 362 (51.9)
HER-2 0.693 0.800
Negative 34 (82.9) 539 (79.3) 20 (83.3) 553 (79.3)
Positive 7 (17.1) 141 (20.7) 4 (16.7) 144 (20.7)
Tumor stage 0.750 0.213
T1 21 (51.2) 329 (48.4) 15 (62.5) 335 (48.1)
T2/T3 20 (48.8) 351 (51.6) 9 (37.5) 362 (51.9)
Nodal stage 0.625 0.529
N0 26 (63.4) 399 (58.7) 16 (66.7) 409 (58.7)
N1/N2/N3 15 (36.6) 281 (41.3) 8 (33.3) 288 (41.3)
Molecular subtypes 0.452 0.134
Luminal A 21 (51.2) 281 (41.3) 15 (62.5) 287 (41.2)
Luminal B 8 (19.5) 160 (23.5) 3 (12.5) 165 (23.7)
HER-2 5 (12.2) 64 (9.4) 3 (12.5) 66 (9.5)
TNBC 7 (17.1) 175 (25.7) 3 (12.5) 179 (25.7)
Ki-67 LI (%, mean ± SD) 13.0 ± 12.3 17.5 ± 18.7 0.127 9.9 ± 10.0 17.5 ± 18.6 0.046
Tumor recurrence 4 (9.8) 59 (8.7) 0.775 1 (4.2) 62 (8.9) 0.714
Patient death 4 (9.8) 56 (8.2) 0.768 1 (4.2) 59 (8.5) 0.713
SDH succinate dehydrogenase, TNBC triple negative breast cancer.
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Table 6 Clinicopathologic characteristics breast cancer by expression of HIF-1α and SDH
Parameters Nuclear HIF-1α Cytoplasmic HIF-1α Tumor SDHA Stromal SDHA Tumor SDHB Stromal SDHB
- + P - + P -* + P - + P -* + P - + P
Histologic grade 0.270 0.601 0.342 0.105 0.870 0.528
I/II 465 (66.7) 19 (79.2) 482 (67.2) 2 (50.0) 248 (68.9) 236 (65.4) 452 (68.0) 32 (57.1) 182 (67.7) 302 (66.8) 433 (67.6) 51 (63.8)
III 232 (33.3) 5 (20.8) 235 (32.8) 2 (50.0) 112 (31.2) 125 (34.6) 213 (32.0) 24 (42.9) 87 (32.3) 150 (33.2) 208 (32.4) 29 (36.3)
ER 0.388 1.000 0.044 0.111 0.873 0.806
Negative 250 (35.9) 11 (45.8) 260 (36.3) 1 (25.0) 117 (32.5) 144 (39.9) 235 (35.3) 26 (46.4) 96 (35.7) 165 (36.5) 231 (36.0) 30 (37.5)
Positive 447 (64.1) 13 (54.2) 457 (63.7) 3 (75.0) 243 (67.5) 217 (60.1) 430 (64.7) 30 (53.6) 173 (64.3) 287 (63.5) 410 (64.0) 50 (62.5)
PR 0.011 1.000 0.118 0.165 0.645 1.000
Negative 328 (47.1) 18 (75.0) 344 (48.0) 2 (50.0) 162 (45.0) 184 (51.0) 314 (47.2) 32 (57.1) 126 (46.8) 220 (48.7) 308 (48.0) 38 (47.5)
Positive 369 (52.9) 6 (25.0) 373 (52.0) 2 (50.0) 198 (55.0) 177 (49.0) 351 (52.8) 24 (42.9) 143 (53.2) 232 (51.3) 333 (52.0) 42 (52.5)
HER-2 0.304 1.000 0.021 0.083 0.057 <0.001
Negative 556 (79.8) 17 (70.8) 570 (79.5) 3 (75.0) 299 (83.1) 274 (75.9) 534 (80.3) 39 (69.6) 224 (83.3) 349 (77.2) 526 (82.1) 47 (58.8)
Positive 141 (20.2) 7 (29.2) 147 (20.5) 1 (25.0) 61 (16.9) 87 (24.1) 131 (19.7) 17 (30.4) 45 (16.7) 103 (22.8) 115 (17.9) 33 (41.3)
Tumor stage 0.304 1.000 0.031 1.000 0.011 0.237
T1 341 (48.9) 9 (37.5) 348 (48.5) 2 (50.0) 160 (44.4) 190 (52.6) 323 (48.6) 27 (48.2) 114 (42.4) 236 (52.2) 306 (47.7) 44 (55.0)
T2/T3 356 (51.1) 15 (62.5) 369 (51.5) 2 (50.0) 200 (55.6) 171 (47.4) 342 (51.4) 29 (51.8) 155 (57.6) 216 (47.8) 335 (52.3) 36 (45.0)
Nodal stage 0.208 0.648 0.198 0.575 0.639 0.149
N0 414 (59.4) 11 (45.8) 422 (58.9) 3 (75.0) 221 (61.4) 204 (56.5) 394 (59.2) 31 (55.4) 162 (60.2) 263 (58.2) 384 (59.9) 41 (51.3)
N1/N2/N3 283 (40.6) 13 (54.2) 295 (41.1) 1 (25.0) 139 (38.6) 157 (43.5) 271 (40.8) 25 (44.6) 107 (39.8) 189 (41.8) 257 (40.1) 39 (48.8)
SDH succinate dehydrogenase.
*includes negative and low-positive cases.
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Table 7 Clinicopathologic features according to the SDH expression phenotype in breast cancer
Factors Tumor phenotype Stroma phenotype
SDHA (+)/ SDHB
(+) n = 679 (%)
SDHA (+)/ SDHB
(−) n = 1 (%)
SDHA (−)/ SDHB
(+) n = 18 (%)
SDHA (-)/ SDHB
(−) n = 23 (%)
P SDHA (+)/ SDHB
(+) n = 42 (%)
SDHA (+)/ SDHB
(−) n = 14 (%)
SDHA (−)/ SDHB
(+) n = 38 (%)
SDHA (−)/ SDHB
(−) n = 627 (%)
P
Histologic grade 0.038 0.150
I/II 450 (66.3) 1 (100.0) 13 (72.2) 20 (87.0) 25 (59.5) 7 (50.0) 26 (68.4) 426 (67.9)
III 229 (33.7) 0 (0.0) 5 (27.8) 3 (13.0) 17 (40.5) 7 (50.0) 12 (31.6) 201 (32.1)
Tumor stage 0.495 0.640
T1 329 (48.5) 0 (0.0) 6 (33.3) 15 (65.2) 20 (47.6) 7 (50.0) 24 (63.2) 299 (47.7)
T2/T3 350 (51.5) 1 (100.0) 12 (66.7) 8 (34.8) 22 (52.4) 7 (50.0) 14 (36.8) 328 (52.3)
Nodal stage 0.491 0.314
N0 398 (58.6) 1 (100.0) 11 (61.1) 15 (65.2) 21 (50.0) 10 (71.4) 20 (52.6) 374 (59.6)
N1/N2/N3 281 (41.4) 0 (0.0) 7 (38.9) 8 (34.8) 21 (50.0) 4 (28.6) 18 (47.4) 253 (40.4)
ER 0.284 0.205
Negative 248 (36.5) 1 (100.0) 7 (38.9) 5 (21.7) 16 (38.1) 10 (71.4) 14 (36.8) 221 (35.2)
Positive 431 (63.5) 0 (0.0) 11 (61.1) 18 (78.3) 26 (61.9) 4 (28.6) 24 (63.2) 406 (64.8)
PR 0.793 0.336
Negative 324 (47.7) 1 (100.0) 11 (61.1) 10 (43.5) 21 (50.0) 11 (78.6) 17 (44.7) 297 (47.4)
Positive 355 (52.3) 0 (0.0) 7 (38.9) 13 (56.5) 21 (50.0) 3 (21.4) 21 (55.3) 330 (52.6)
HER-2 0.567 0.001
Negative 539 (79.4) 0 (0.0) 14 (77.8) 20 (87.0) 26 (61.9) 13 (92.9) 21 (55.3) 513 (81.8)
Positive 140 (20.6) 1 (100.0) 4 (22.2) 3 (13.0) 16 (38.1) 1 (7.1) 17 (44.7) 114 (18.2)
Molecular type 0.057 <0.001
Luminal A 281 (41.4) 0 (0.0) 6 (33.3) 15 (65.2) 14 (33.3) 2 (14.3) 11 (28.9) 275 (43.9)
Luminal B 160 (23.6) 0 (0.0) 5 (27.8) 3 (13.0) 13 (31.0) 2 (14.3) 13 (34.2) 140 (22.3)
HER-2 63 (9.3) 1 (100.0) 3 (16.7) 2 (8.7) 9 (21.4) 1 (7.1) 9 (23.7) 50 (8.0)
TNBC 175 (25.8) 0 (0.0) 4 (22.2) 3 (13.0) 6 (14.3) 9 (64.3) 5 (13.2) 162 (25.8)
Ki-67 LI (%, mean ± SD) 17.5 ± 18.7 8.0 ± 0.0 16.8 ± 14.0 10.0 ± 10.2 0.260 17.8 ± 15.3 24.3 ± 22.8 22.1 ± 19.0 16.8 ± 18.4 0.161
Tumor recurrence 59 (8.7) 0 (0.0) 3 (16.7) 1 (4.3) 0.955 4 (9.5) 1 (7.1) 2 (5.3) 56 (8.9) 0.877
Patient death 56 (8.2) 0 (0.0) 3 (16.7) 1 (4.3) 0.968 3 (7.1) 1 (7.1) 3 (7.9) 53 (8.5) 0.727
SDH succinate dehydrogenase.
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Table 8 Univariate analysis of disease-free survival and overall survival according to breast-tumor expression of
hypoxia-related proteins
Parameters Number of patients/
recurrence/death
Disease-free survival Overall survival
Mean survival
(95% CI) months
P -value Mean survival
(95% CI) months
P -value
Nuclear HIF-1α 0.911 0.943
Negative 697/61/58 126 (122 − 130) 129 (127 − 132)
Positive 24/2/2 120 (108 − 133) 131 (122 − 141)
Cytoplasmic HIF-1α N/A N/A
Negative 717/63 N/A N/A
Positive 4/0 N/A N/A
Tumoral SDHA 0.670 0.085
Negative/Low 360/35/26 125 (121 − 129) 131 (128 − 135)
High 361/28/34 126 (120 − 132) 126 (121 − 130)
Stromal SDHA 0.853 0.901
Negative 665/58/56 126 (123 − 130) 130 (127 − 132)
Positive 56/5/4 115 (101 − 130) 121 (107 − 134)
Tumoral SDHB 0.124 0.715
Negative/Low 269/31/26 123 (119 − 128) 129 (125 − 133)
High 452/32/34 126 (121 − 131) 129 (125 − 132)
Stromal SDHB 0.821 0.981
Negative 641/57/54 126 (122 − 130) 130 (127 − 132)
Positive 80/6/6 119 (110 − 128) 123 (114 − 131)
SDH succinate dehydrogenase P-value by log-rank test.
Table 9 Multivariate analysis for breast-cancer survival
Parameters Disease-free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
T stage 0.003 0.008
T1 versus T2-3 2.535 1.376 − 4.670 2.218 1.229 − 4.001
N stage 0.002 0.026
N0 versus N1-3 2.257 1.335 − 3.816 1.831 1.076 − 3.115
Histologic grade 0.045 0.372
I/II versus III 1.685 1.013 − 2.804 1.276 0.748 − 2.176
Nuclear HIF-1α 0.599 0.486
Negative versus Positive 0.682 0.163 − 2.846 0.599 0.142 − 2.528
Tumor SDHA 0.290 0.002
Negative/Low versus High 1.570 0.681 − 3.620 4.157 1.657 − 10.432
Stromal SDHA 0.727 0.747
Negative versus Positive 1.254 0.352 − 4.468 0.807 0.218 − 2.978
Tumor SDHB 0.096 0.012
Negative/Low versus High 0.498 0.219 − 1.131 3.223 1.295 − 8.025
Stromal SDHB 0.712 0.965
Negative versus Positive 0.802 0.248 − 2.590 0.976 0.327 − 2.908
SDH succinate dehydrogenase.
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negative (complete loss of expression); grade (2), low
(expression in less than 50% of cells); and grade (3)
high (expression in more than 50% of cells).
Several mechanisms have been proposed to explain
the involvement of SDH mutation in tumorigenesis,
among which a HIF-1α-pathway-dependent mechanism
is the most famous. Loss-of-function mutation of SDH
could result in an intracellular SDH accumulation, which
in turn inhibits prolyl 4-hydroxylase (PHD), a negative
regulator of HIF-1α (Cardaci & Ciriolo 2012; Barletta &
Hornick 2012). The impaired PHD activity stabilizes
HIF-1α under normoxic condition, which upregulates
HIF target gene involved in cell growth stimulation and
angiogenesis, thus contributing to tumor progression. As
loss-of-function mutations in SDH are predicted to
stabilize HIF-1α and upregulate HIF-1 transcriptional
activity, we examined the expression of HIF-1α along
with SDHA/SDHB. However, we found no close rela-
tionship between HIF-1α and SDH expression in these
breast cancers.
SDH-deficient GISTs and renal cell carcinomas display
characteristic histologic features distinguishable from tu-
mors without SDH mutation (Miettinen et al. 2011; Gill
et al. 2011b). Similarly, the SDHA+/SDHB- and SDHA-
/SDHB- breast cancers in this study were distinguished by
lower histologic grade (Table 7), and in the SDHB-negative
tumors, by lower Ki-67 LI (Table 5). The luminal A breast
cancer subtype showed the highest frequency of low/nega-
tive SDHA expression (P= 0.032, Table 3). Based on these
results, SDH mutation in breast cancer is associated with
low histologic grade and a less aggressive molecular subtype.
Patients with SDHA- and SDHB-negative breast can-
cers were also younger than patients with intact SDH
expression, although in the case of SDHB, this difference
was not statistically significant. In earlier studies of SDH
mutations in renal cell carcinomas (Baysal 2003), GISTs
(Miettinen et al. 2011), paragangliomas, and pheochro-
mocytomas (Gimenez-Roqueplo et al. 2003), tumors also
occurred at younger ages.
Metabolism in many malignant tumors is characterized
by the Warburg effect, which is a high level of anaerobic
glucose metabolism by glycolysis despite presence of oxy-
gen with relatively low mitochondrial oxidative phosphor-
ylation (OXPHOS) (Warburg 1956). In this study, more
than 50% of breast cancers expressed SDHA and SDHB,
which are key components of aerobic glucose metabolism
through the TCA cycle and mitochondrial electron trans-
port. This finding of high mitochondrial activity in breast
cancer agrees with an earlier report that breast cancer
cells show high expression of mitochondrial metabolic en-
zymes such as cytochrome C oxidase, NADH, and SDHB
(Whitaker-Menezes et al. 2011).
Expression of Glut-1 and CAIX (indicators of glycoly-
sis) has also been observed in breast cancers, most
notably in high-grade tumors such as TNBC or basal-
like carcinoma (Choi et al. 2013; Pinheiro et al. 2011).
While breast cancers overall may express high levels of
activity in both OXPHOS and glycolysis, the predomin-
ant mode of energy metabolism may differ according to
the tumor type (Moreno-Sanchez et al. 2007: Kallinowski
et al. 1989; Liu et al. 2001).
Although most breast cancers in this study were negative
for SDH in stromal elements, stromal SDHB expression
differed significantly among the molecular subtypes. The
HER-2 subtype showed the highest and TNBC showed the
lowest frequency of stromal SDHB expression (Table 3).
However, in a previous study, stromal cells in breast cancer
did not express mitochondrial metabolic enzymes (cyto-
chrome c oxidase, NADH, or SDHB) (Whitaker-Menezes
et al. 2011). Further studies will be required to determine
the differences in stromal SDHB expression among breast
cancer molecular subtypes.
In conclusion, loss of SDHA or SDHB expression was
detected in approximately 3% of the breast cancers in
this study. Patients with SDH-deficient breast cancers
were younger at diagnosis and presented tumors of rela-
tively low-grade histology.
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